Glucagon-like Peptide 1 (GLP-1) Medications

Welcome to Dr. David Nazarian’s premier weight loss clinic in Los Angeles. Our weight loss center has extensive use with glucagon-like peptide-1 receptor agonists and their benefits in weight loss, PCOS and diabetes. Schedule a consult with our weight loss specialist today and see how we can help you achieve your weight loss goals.

Glucagon-like Peptide 1 (GLP-1) Medications

Glucagon-like-peptide-1 drugs

 

If you are considering weight loss, GLP-1 medications are a way to achieve results. At Weight Loss Clinic Los Angeles, we offer GLP-1 treatments to help you lose way in the most convenient way possible. 

Let’s take a look at what GLP-1 medications are and how they help patients achieve weight loss.

 

What are GLP-1 medications?

 

Glucagon-like peptide-1 agonists are a type of medicine used to treat type 2 diabetes [1]. Some GLP-1 agonists like Wegovy and Ozempic can help in weight loss as well.

For now, Semaglutide and Liraglutide are two FDA-approved GLP-1 medicines that can be used for weight loss and are prescribed by doctors to their patients [2]. Studies have shown results of using these two medications for weight loss.

Doctors also prescribe these medications to patients who can’t lose weight or have other health conditions such as diabetes or heart disease.

 

How GLP-1 Medications Work

 

These medications work by mimicking glucagon-like peptide 1 (GLP-1). GLP-1 is a natural hormone found in our bodies that helps in maintaining blood sugar levels, suppressing hunger, and increases feelings of fullness [3].

The agonists do exactly that and mimic the functions of the hormone, thus helping patients with diabetes and obesity.

 

How does GLP-1 suppress appetite?

 

Our intestines produce the hormones that influence our digestive system’s functions. The hormone delays the emptying of the stomach, which means that it takes a longer time for the food to be digested and absorbed. The delay makes us feel fuller for a longer period of time [4].

Types of GLP-1 Agonists

 

Wegovy (semaglutide)

Wegovy (semaglutide) has been approved by the Food and Drug Administration (FDA) for weight loss in 2021. The semaglutide injection needs to be received once per week. The dosage for the first 16 weeks ranges in small doses (0.25-1.7 mg). The small dosage is given to check how the patient’s body tolerates the dosage, and based on that, the dosage can be increased to 2.4 mg per week.

Effectiveness

 

Multiple studies conducted in 2021 stated that 2.4 milligrams of Wegovy once a week could help in weight loss among patients. According to those studies Wegovy was more effective compared to placebo [5].

Two studies with 803 and 1,961 participants with obesity suggested reductions in waist size, hemoglobin levels, systolic blood pressure, and cholesterol. Both studies experimented with a 2.4 mg Wegovy dosage to the participants and found a 7.9 – 14.9% decrease in body weight [6, 7].

Saxenda (liraglutide)

 

Saxenda is another injectable drug that was approved by the FDA in 2020 for weight management in children of 12 years or older. However, proper diet and exercise are also needed alongside the injection to see significant changes. It is recommended to use 3 mg of Saxenda is recommended for the patients. The starting dose should be as low as 0.6 mg per day, and then the dosage should be increased weekly until the recommended dosage (3 mg)  is reached.

Effectiveness

 

A 2021 study with 169 candidates with obesity found that 62.1% of them lost at least 5% of their body weight in 6 months using liraglutide. While, 17.2% of the participants and reported to have at least 10% of weight reduction [8].

Another study conducted in 2021 showed 277 subjects taking 3 mg liraglutide per day lost 9 pounds (4.1 kg) [9].

Ozempic (semaglutide)

The approved drug Ozempic is used to improve blood sugar levels in adults with type 2 diabetes. Although Wegovy and Ozempic are the same, Ozempic is available in a lower dose and isn’t specifically used for weight loss. The recommended dosage is 0.25 mg once a week and then increasing the dosage to 0.5 mg after 4 weeks. Based on the doctor’s observation, the dosage can be increased up to 1 or 2 mg per week.

Effectiveness

 

In a 2018 study, participants with type 2 diabetes found that both 1 mg (high) and 0.5 mg (low) dosages of Ozempic were more effective than Trulicity (dulaglutide) [10].

Mounjaro (tirzepatide)

 

Another FDA-approved GLP-1 agonist, Mounjaro, is used to improve blood sugar levels in combination with diet and exercise in adults with type 2 diabetes. The starting dose for Mounjaro is 2.5 mg once per week. After 4 weeks have passed, the doctor can increase the dosage to 5 mg. Considering the patient’s tolerance, the dosage can be increased up to 15 mg once a week.

Effectiveness

 

A 2022 study about the 5, 10, and 15 mg weekly dosage of tirzepatide can cause weight loss in obese or overweight people. After 72 weeks, subjects lost 15% for 5 mg, 19.5% for 10 mg, and 20.9% for 15 mg of weight overall [11].

Another study in that year with 259 people found that using tirzepatide for 26 weeks not only caused weight loss but also improved blood sugar levels and improves metabolic health [12].

How it works

Contact us at +1 424-283-4273 to schedule an in office consult or virtual consult

or Book Online to receive your prescription of Wegovy or other Semaglutide or Trizepatide for weight loss.

  • Virtual Consult with MD & Nutritionist $450
  • 3 Month Supply of the best compounded semaglutide injection  $750 ( Special Pricing) 
  • Follow Ups $250
  • Lose 10 – 20% of body fat safely and effectively
Dr. David Nazarian

Rybelsus (semaglutide)

Rybelsus is an oral drug used for adults with type 2 diabetes. It’s also recently approved as a treatment for adults with type 2 diabetes who have not used other diabetes treatments. The pill should be taken with water 30 minutes before eating. A starting dosage of 3 mg daily for 30 days is recommended at first. Depending on the outcome, the dosage can be increased to 7-14 mg. 

Effectiveness

A review of 11 studies in 2019 suggested that oral semaglutide is much more effective at reducing HbA1c levels and weight loss compared to other medications used for diabetes, which includes liraglutide [13].

Trulicity (dulaglutide)

The injection Trulicity is used once a week alongside diet and exercise to treat type 2 diabetes in adults. The starting dose of Trulicity is 0.75 mg once per week and can be topped up to 3 – 4.5 mg per week under the doctor’s supervision.

Effectiveness

A 2020 study with 1,307 participants taking dulaglutide found that it reduced HbA1c by 1%. It also decreased the body weight by an average of 6.4 pounds (2.9 kg) during a follow-up period of 30 months [14].

Another 2021 study found that people with diabetes lost 6.8 lb for 1.5 mg, 8.8 lb for 3mg, or 10.4 lb for 4.5 mg of dulaglutide after 36 weeks [15].

Victoza (liraglutide)

Victoza is an injectable medication for type 2 diabetes in adult patients. It’s taken once a day to treat diabetes and obesity. It can also help in minimizing the risk of heart attack and stroke in adult patients with type 2 diabetes. The starting dosage of Victoza should be 0.6 mg per day and can be increased to 1.2 mg per day after 7 days. Based on the doctor’s observation, the dosage may be increased to 1.8 mg per day. 

Effectiveness

A study published in 2019 reported that a group of 40 people with type 2 diabetes and obesity/overweight found 1.8 mg of Victoza to be effective for sustainable weight loss. Subjects lost 11 pounds (5 kg) and had low blood sugar levels after 5 years [16].

Byetta (exenatide)

Byetta is another injectable used to manage blood sugar levels in diabetic patients combined with proper diet and exercise. Byetta is injected an hour before two main meals of the day. A little dosage of 5 mcg (micrograms) should be injected at first. After a month, the dosage can be increased to 10 mcg if needed. 

Effectiveness

A 2016 study showed that adolescents and young adults with weight issues and Prader-Will syndrome had a decreased appetite after 30 days and improved long-term blood sugar levels [17].

Bydureon BCise (exenatide)

Bydureon BCise is another injectable drug used for improving blood sugar levels in patients with diabetes. A dosage of 2 mg is prescribed once per week and can be taken any time of day. 

Effectiveness

A 12-week study published in 2021 found that combining Bydureon BCise with Metformin was more effective in body weight, BMI and belly fat reductions compared to using Metformin alone. The study also stated that the combined medication improved insulin sensitivity in women with PCOS and obesity [18].

Comparative Studies

Comparative Studies

Wegovy vs. Saxenda

A 2022 study with 338 people collectively compared the effectiveness of Wegovy with Saxenda paired with diet and exercise regime. After 68 weeks, it was reported that patients taking Wegovy lost more weight than those who took Saxenda [19].

Ozempic vs. Victoza

A 2019 study conducted with 577 people with type 2 diabetes compared the effects of Ozempic and Victoza. The result showed that Ozempc was able to improve blood sugar management for the longer term and caused participants to lose over 3 times the amount of weight lost by Victoza [20].

Semaglutide vs. Liraglutide vs. Placebo

A study conducted in 2019 compared the effectiveness of semaglutide (14 mg), liraglutide (1.8 mg) and a placebo amongst a group of 711 type 2 diabetes patients. The report stated that both semaglutide and liraglutide were similarly effective at lowering HbA1c levels.

The only difference is patients who took semaglutide lost more body weight after 26 weeks than those who took liraglutide or a placebo [21].

Liraglutide vs Placebo

Another similar study in 2021 found that liraglutide helped reduce BMI and body weight over a year compared to Placebo in children and adolescents with type 2 diabetes [22].

Exenatide vs Placebo

A compilation of six studies in 2016 found that exenatide helped in a greater reduction of body weight, belly fat, and BMI compared to a placebo. The studies were conducted with people who are obese or overweight but don’t suffer from diabetes [23].

Bydureon BCise vs. Byetta

The 2013 review of Bydureon BCise noted that it could decrease HbA1c levels by 1.6% with fewer digestive side effects compared to Byetta [24].

Glucagon-like Peptide 1 Medications Near Me

Weight Loss Clinic LA offers the best Glucagon-like Peptide 1 Medications near me in Beverly Hills but can also come to your home or office throughout the Los Angeles area. We serve patients near Beverly Hills, Bel Air, West Hollywood, Santa Monica, West Los Angeles, Culver City, Hollywood, Venice, Marina del Rey, Malibu, Manhattan Beach, Redondo Beach, Downtown Los Angeles, Encino, Woodland Hills, Sherman Oaks, Calabasas, Burbank, Glendale, Hidden Hills, Agoura Hills, Northridge, North Hollywood, Topanga, Canoga Park, Reseda, Valley Glen, Chatsworth, West Hills, Winnetka, Universal City, Silverlake, Echo Park, and many more.

References:

  1. Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. [Updated 2023 Jan 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551568/
  2. Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. [Updated 2023 Jan 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551568/
  3. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. doi:10.1016/j.molmet.2019.09.010
  4. Shah M, Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord. 2014;15(3):181-187. doi:10.1007/s11154-014-9289-5
  5. Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022;70(1):5-13. doi:10.1136/jim-2021-001952
  6. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224
  7. Wilding J, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine. 2021;384(11):989-1002. doi:https://doi.org/10.1056/nejmoa2032183
  8. Park JS, Kwon J, Choi HJ, Lee C. Clinical effectiveness of liraglutide on weight loss in South Koreans: First real-world retrospective data on Saxenda in Asia. Medicine (Baltimore). 2021;100(2):e23780. doi:10.1097/MD.0000000000023780
  9. Haase CL, Serratore Achenbach MG, Lucrezi G, Jeswani N, Maurer S, Egermann U. Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland. Obes Facts. 2021;14(5):568-576. doi:10.1159/000518325
  10. Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, Vergès B, Marre M. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020 Apr;46(2):100-109. doi: 10.1016/j.diabet.2019.101117. Epub 2019 Sep 17. PMID: 31539622.
  11. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.
  12. Pirro V, Roth KD, Lin Y, Willency JA, Milligan PL, Wilson JM, Ruotolo G, Haupt A, Newgard CB, Duffin KL. Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes. J Clin Endocrinol Metab. 2022 Jan 18;107(2):363-378. doi: 10.1210/clinem/dgab722. PMID: 34608929.
  13. Avgerinos I, Michailidis T, Liakos A, Karagiannis T, Matthews DR, Tsapas A, Bekiari E. Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 2020 Mar;22(3):335-345. doi: 10.1111/dom.13899. Epub 2019 Nov 20. PMID: 31637820.
  14. Morieri ML, Frison V, Rigato M, D’Ambrosio M, Tadiotto F, Paccagnella A, Simioni N, Lapolla A, Avogaro A, Fadini GP. Effectiveness of Dulaglutide in the Real World and in Special Populations of Type 2 Diabetic Patients. J Clin Endocrinol Metab. 2020 Jul 1;105(7):dgaa204. doi: 10.1210/clinem/dgaa204. PMID: 32301492.
  15. Bonora E, Frias JP, Tinahones FJ, et al. Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11. Diabetes Obes Metab. 2021;23(10):2242-2250. doi:10.1111/dom.14465
  16. Mirabelli M, Chiefari E, Caroleo P, et al. Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes. Int J Environ Res Public Health. 2019;17(1):207. Published 2019 Dec 27. doi:10.3390/ijerph17010207
  17. Salehi P, Hsu I, Azen CG, Mittelman SD, Geffner ME, Jeandron D. Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome. Pediatr Obes. 2017;12(3):221-228. doi:10.1111/ijpo.12131
  18. Ma RL, Deng Y, Wang YF, Zhu SY, Ding XS, Sun AJ. Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome. Chin Med J (Engl). 2021;134(23):2882-2889. Published 2021 Nov 3. doi:10.1097/CM9.0000000000001712
  19. Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138-150. doi:10.1001/jama.2021.23619
  20. Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, Vergès B, Marre M. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020 Apr;46(2):100-109. doi: 10.1016/j.diabet.2019.101117. Epub 2019 Sep 17. PMID: 31539622.
  21. Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, Pedersen KB, Saugstrup T, Meier JJ; PIONEER 4 investigators. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019 Jul 6;394(10192):39-50. doi: 10.1016/S0140-6736(19)31271-1. Epub 2019 Jun 8. Erratum in: Lancet. 2019 Jul 6;394(10192):e1. PMID: 31186120.
  22. Bensignor MO, Bomberg EM, Bramante CT, et al. Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial. Pediatr Obes. 2021;16(8):e12778. doi:10.1111/ijpo.12778
  23. Su N, Li Y, Xu T, Li L, Kwong JS, Du H, Ren K, Li Q, Li J, Sun X, Li S, Tian H. Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials. Int J Cardiol. 2016 Sep 15;219:293-300. doi: 10.1016/j.ijcard.2016.06.028. Epub 2016 Jun 15. PMID: 27343423.
  24. Nathan A. Painter, Candis M. Morello, Renu F. Singh, Sarah E. McBane. The Journal of the American Board of Family Medicine Mar 2013, 26 (2) 203-210; DOI: 10.3122/jabfm.2013.02.120174

Book Appointment

"*" indicates required fields

Step 1 of 3

Name*
Address*
*Please use ZIP code that matches your Credit Card otherwise it will be declined.
Our Staff will contact you to Confirm and Schedule time of Appointment